Physician profile
Howard J Raphael
NPI 1881639797
$524.39
in general payments reported to CMS, 2019-2025
15 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.15 · 2021: $31.52 · 2023: $168 · 2024: $181 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $90.76 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $85.69 | 2023-2024 | Freestyle Libre |
| Abbvie INC. | $76.60 | 2021-2025 | |
| Pfizer INC. | $55.59 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.00 | 2023-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $34.62 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $22.16 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $19.83 | 2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $19.07 | 2025 | |
| Lilly USA, LLC | $17.05 | 2024 | Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $15.02 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $14.71 | 2019 | |
| Exact Sciences Corporation | $13.85 | 2025 | Cologuard Collection Kit |
| Melinta Therapeutics, LLC | $11.44 | 2019 | |
| Genentech USA, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Raphael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.